Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
Phase 1/2
67
about 10 years
18–74
1 site in NY
What this study is about
This trial is testing a treatment with capecitabine and temozolomide for newly diagnosed glioblastoma multiforme (GBM). The goal is to determine if this combination is safe and effective, comparing it to standard temozolomide alone.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Capecitabine
- 2.Take Temozolomide
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
capecitabine, temozolomide
oral (Oral Tablet), injection, intravenous
Primary: Overall Survival (OS), Progression-free survival (PFS)
Secondary: Composite overall response rate (CORR) through the Response Evaluation Criteria In Solid Tumors (RECIST), Toxicities will be tabulated and graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03.
Neurology, Oncology